Effect of deep testosterone reduction on the prognosis of metastatic prostate cancer with high-volume disease
Patients with high-volume disease mPCa who receive CAB treatment may experience extended progression-free survival and overall survival if their serum testosterone levels are below 0.7 nmol/l after one month of treatment. The longer it takes to achieve DTR, the worse the patient's prognosis may be. The nomogram prediction model developed in this study demonstrates good predictive ability in assessing the progression and prognosis of high-volume disease mPCa.
Authors
- Xin Huang (ORCID: https://orcid.org/0000-0002-0413-3340)
- Tao Zhuo (ORCID: https://orcid.org/0000-0001-8860-1887)
- Zhuang Lei
- Hengqing An (ORCID: https://orcid.org/0009-0003-7738-8824)
- Yujie Wang (ORCID: https://orcid.org/0000-0003-4326-720X)
- Ning Tao (ORCID: https://orcid.org/0000-0001-6027-5039)
- Xiangyue Yao
- Hudie Yang
Institutions
- Xinjiang Medical University (CN)
- Fifth Affiliated Hospital of Xinjiang Medical University (CN)
- First Affiliated Hospital of Xinjiang Medical University (CN)
- Second Affiliated Hospital of Xinjiang Medical University (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1007/s00432-024-05865-5
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- National Natural Science Foundation of China
- Xinjiang Medical University
- Natural Science Foundation of Xinjiang